Updated NETs Clinical Trials

Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
  1. Conditions:   Metastatic Prostate Neuroendocrine Carcinoma;   Metastatic Prostate Cancer
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Carboplatin;   Drug: Cabazitaxel
    Sponsors:   Andrew J. Armstrong, MD;   Bristol-Myers Squibb
    Recruiting
  2. Conditions:   VHL Pancreatic Neuroendocrine Tumors;   Von Hippel-Lindau Disease;   Neuroendocrine Tumors
    Intervention:   Drug: 68-Gallium DOTATATE
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  3. Conditions:   Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma;   Recurrent Small Cell Neuroendocrine Carcinoma;   Small Cell Neuroendocrine Carcinoma
    Interventions:   Biological: Atezolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  4. Conditions:   Small-cell Lung Cancer;   Neuroendocrine Carcinoma
    Interventions:   Drug: Iadademstat;   Drug: Paclitaxel
    Sponsor:   Fox Chase Cancer Center
    Not yet recruiting
  5. Conditions:   EGFR-Mutated Non-Small-Cell Lung Carcinoma;   Small Cell/Neuroendocrine
    Interventions:   Drug: Olaparib;   Drug: Durvalumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  6. Conditions:   Pheochromocytoma/Paraganglioma;   Pancreatic Neuroendocrine Tumor;   Von Hippel-Lindau Disease
    Intervention:   Drug: Belzutifan
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting
  7. Conditions:   Locally Advanced Digestive System Neuroendocrine Carcinoma;   Locally Advanced Pancreatic Neuroendocrine Carcinoma;   Metastatic Digestive System Neuroendocrine Carcinoma;   Metastatic Pancreatic Neuroendocrine Carcinoma;   Refractory Digestive System Neuroendocrine Carcinoma;   Refractory Pancreatic Neuroendocrine Carcinoma;   Unresectable Digestive System Neuroendocrine Carcinoma;   Unresectable Pancreatic Neuroendocrine Carcinoma
    Interventions:   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Liposomal Irinotecan;   Procedure: Quality-of-Life Assessment
    Sponsors:   Roswell Park Cancer Institute;   Ipsen
    Recruiting
  8. Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Locally Advanced Pancreatic Neuroendocrine Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Tumor G1;   Metastatic Pancreatic Neuroendocrine Tumor;   Metastatic Thymic Neuroendocrine Neoplasm;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Serotonin-Producing Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  9. Conditions:   Locally Advanced Neuroendocrine Neoplasm;   Metastatic Neuroendocrine Neoplasm
    Interventions:   Drug: Placebo Administration;   Other: Questionnaire Administration;   Drug: Telotristat Ethyl
    Sponsors:   M.D. Anderson Cancer Center;   TerSera Therapeutics LLC
    Recruiting
  10. Conditions:   Gastroenteropancreatico Tumors;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Olaparib;   Diagnostic Test: Ga dotatate scanning;   Diagnostic Test: FDG-PET scanning
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  11. Conditions:   SCLC;   Small Cell Cancer;   Advanced Solid Tumor;   High Grade Neuroendocrine Cancers
    Interventions:   Drug: Lurbinectedin;   Drug: Berzosertib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  12. Conditions:   Gastroenteropancreatic Neuroendocrine Tumors;   Pheochromocytoma;   Paraganglioma
    Intervention:   Drug: Lutetium [177Lu] oxodotreotide/dotatate
    Sponsor:   Advanced Accelerator Applications
    Recruiting
  13. Conditions:   Advanced Adrenal Gland Pheochromocytoma;   Advanced Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Paraganglioma;   Unresectable Adrenal Gland Pheochromocytoma;   Unresectable Paraganglioma
    Interventions:   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  14. Conditions:   Advanced Solid Tumor;   Metastatic Solid Tumor;   Urothelial Carcinoma;   Large Cell Neuroendocrine Carcinoma of the Lung;   Homologous Recombination Deficiency
    Intervention:   Drug: Lurbinectedin
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  15. Conditions:   Transgender;   Healthy
    Interventions:   Drug: Testosterone Cyp 200Mg/Ml Inj (in Oil);   Drug: Letrozole
    Sponsor:   University of California, San Diego
    Not yet recruiting
  16. Conditions:   Locally Advanced Solid Tumor;   Metastatic Solid Tumor
    Intervention:   Drug: JBI-802
    Sponsor:   Jubilant Therapeutics Inc.
    Recruiting
  17. Conditions:   Pheochromocytoma;   Paraganglioma;   Neuroendocrine Tumors;   Neuroendocrine Neoplasms
    Interventions:   Drug: Lu-177-DOTATATE;   Drug: Ga-68-DOTATATE;   Drug: F-18-FDG;   Drug: Amino Acid solution
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  18. Conditions:   Bile Duct Cancer;   Gall Bladder Cancer;   Breast Cancer;   Neuroendocrine Tumors;   Ovarian Cancer;   Pancreatic Adenocarcinoma;   Soft Tissue Sarcoma;   Vulvar Cancer;   Prostate Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Tivozanib
    Sponsors:   University of Florida;   Genentech, Inc.;   Aveo Oncology Pharmaceuticals
    Recruiting
  19. Condition:   Advanced Ovarian Cancer
    Interventions:   Drug: Ropivacaine;   Drug: Saline Solution
    Sponsors:   Karolinska Institutet;   Skane University Hospital
    Recruiting
  20. Conditions:   Bladder Adenocarcinoma;   Bladder Clear Cell Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Neuroendocrine Carcinoma;   Bladder Small Cell Neuroendocrine Carcinoma;   Bladder Squamous Cell Carcinoma;   Bladder Urachal Adenocarcinoma;   Chromophobe Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Neuroendocrine Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Urethral Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IV Urethral Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor;   Urethral Clear Cell Adenocarcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  21. Conditions:   Endocrine/Neuroendocrine;   Non-Small Cell Lung Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Ovarian Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Biological: Sleeping Beauty Transposed PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  22. Condition:   Metastic Thyroid Cancer
    Intervention:   Drug: 68-Gallium-DOTATATE-PET/CT
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  23. Conditions:   Endocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancers;   Neuroendocrine Tumors;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL;   Drug: Pembrolizumab (KEYTRUDA )
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  24. Condition:   Medullary Thyroid Cancer
    Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  25. Conditions:   Advanced Cancer;   Anal Carcinoma;   Anal Cancer;   Biliary Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Neuroendocrine Tumor;   Carcinoid Tumor;   Endometrial Carcinoma;   Endometrial Cancer;   Cervical Carcinoma;   Cervical Cancer;   Vulvar Carcinoma;   Vulvar Cancer;   Small Cell Lung Carcinoma;   Small Cell Lung Cancer (SCLC);   Mesothelioma;   Thyroid Carcinoma;   Thyroid Cancer;   Salivary Gland Carcinoma;   Salivary Gland Cancer;   Salivary Cancer;   Parotid Gland Cancer;   Advanced Solid Tumors;   Colorectal Carcinoma
    Intervention:   Biological: pembrolizumab
    Sponsor:   Merck Sharp & Dohme LLC
    Recruiting
  26. Conditions:   Locally Advanced Solid Tumors;   Metastatic Solid Tumors
    Intervention:   Drug: Oral repotrectinib (TPX-0005)
    Sponsors:   Turning Point Therapeutics, Inc.;   Zai Lab (Shanghai) Co., Ltd.
    Recruiting
  27. Conditions:   Atypical Teratoid/Rhabdoid Tumor;   Epithelioid Sarcoma;   Kidney Medullary Carcinoma;   Malignant Solid Neoplasm;   Poorly Differentiated Chordoma;   Recurrent Atypical Teratoid/Rhabdoid Tumor;   Recurrent Chordoma;   Recurrent Epithelioid Sarcoma;   Recurrent Kidney Medullary Carcinoma;   Recurrent Rhabdoid Tumor;   Refractory Atypical Teratoid/Rhabdoid Tumor;   Refractory Chordoma;   Refractory Epithelioid Sarcoma;   Refractory Kidney Medullary Carcinoma;   Refractory Rhabdoid Tumor;   Rhabdoid Tumor
    Interventions:   Biological: Atezolizumab;   Biological: Tiragolumab
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting
  28. Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Any Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Recruiting
  29. Conditions:   BCC - Basal Cell Carcinoma;   SCC - Squamous Cell Carcinoma;   Merkel Cell Carcinoma;   Keratoacanthoma of Skin;   Malignant Adnexal Tumors of the Skin (MATS);   Tumors From Cutaneous T-cell Lymphoma (CTCL);   Kaposi Sarcoma
    Intervention:   Drug: L19IL2/L19TNF
    Sponsor:   Philogen S.p.A.
    Not yet recruiting
  30. Conditions:   Merkel Cell Carcinoma;   Cutaneous Squamous Cell Carcinoma;   Metastatic Cancer;   Triple Negative Breast Cancer;   Advanced Cancer
    Interventions:   Drug: CMP-001;   Drug: cemiplimab-rwlc
    Sponsors:   Checkmate Pharmaceuticals;   Regeneron Pharmaceuticals
    Recruiting
  31. Conditions:   Advanced Renal Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Collecting Duct Carcinoma;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Papillary Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8;   Unclassified Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radium Ra 223 Dichloride
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  32. Conditions:   Stage III Merkel Cell Carcinoma AJCC v8;   Stage IIIB Merkel Cell Carcinoma AJCC v8;   Stage IIIA Merkel Cell Carcinoma AJCC v8
    Interventions:   Drug: Avelumab;   Other: Peripheral Blood Collection;   Other: Placebo
    Sponsors:   University of Washington;   EMD Serono
    Recruiting
  33. Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  34. Conditions:   Adrenal Gland Pheochromocytoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Malignant Solid Neoplasm;   Paraganglioma
    Interventions:   Drug: Talazoparib;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  35. Condition:   Neurofibromatosis Type 2
    Interventions:   Drug: REC-2282;   Drug: Placebo
    Sponsor:   Recursion Pharmaceuticals Inc.
    Recruiting
  36. Condition:   Merkel Cell Carcinoma
    Interventions:   Drug: KRT-232;   Drug: Avelumab
    Sponsor:   Kartos Therapeutics, Inc.
    Recruiting
  37. Conditions:   Neurofibromatosis Type 2;   Vestibular Schwannoma;   Non-vestibular Schwannoma;   Meningioma;   Ependymoma
    Intervention:   Drug: Brigatinib
    Sponsors:   Scott R. Plotkin, MD, PhD;   Takeda;   The Children's Tumor Foundation
    Recruiting
  38. Conditions:   Vestibular Schwannoma;   Acoustic Neuroma;   Neurofibromatosis 2
    Interventions:   Drug: Aspirin;   Drug: Placebo
    Sponsors:   Massachusetts Eye and Ear Infirmary;   United States Department of Defense;   Massachusetts General Hospital
    Recruiting
  39. Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Choriocarcinoma;   Embryonal Carcinoma;   Immature Teratoma;   Malignant Teratoma;   Mixed Germ Cell Tumor;   Pineal Region Germ Cell Tumor;   Pineal Region Immature Teratoma;   Pineal Region Yolk Sac Tumor;   Suprasellar Germ Cell Tumor
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Mesna;   Biological: Pegfilgrastim;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Procedure: Second-Look Surgery;   Drug: Thiotepa
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting